Forensic Analysis · General / Diversified · as of Sep 6, 2026
Rxsight, Inc. (RXST)
A forensic read on Rxsight, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Safe
Financial health
5.3
Distress distance
Clean
Earnings quality
5
Forensic signals
-5.6
P / E (ttm)
-14.1%
ROE
$250M
Market cap
0.00%
Dividend yield
-3.9%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Rxsight, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads 5.2, placing it in the Safe zone. 5 forensic signals were flagged in its latest SEC filings, led by inventory days.
What the filings flag
311d
FY2024→FY2025
Inventory days.Days inventory outstanding moved from 176 to 311 FY2024→FY2025 (against cost of goods sold; inventory +43% vs -23% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.
-14.3%
FY2025
Return on invested capital.Return on invested capital is -14.3% in the latest fiscal year and rising from -41% — well below its ~9% cost of capital, and it has been across FY2021–FY2025, so reinvested dollars have not been earning their keep.
+13.9%/yr
FY2022–FY2025
Share-count dilution.Diluted share count changed +48% over the last 3 years to FY2025 (+13.9%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~13.9% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~32%.
73d DSO
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 66 to 73 days FY2024→FY2025 (receivables -22% vs revenue -4%). Receivables are creeping up relative to sales. Across FY2022–FY2025 the day count ran 59 → 64 → 66 → 73 days — the latest step continues a climb that was already under way, which is the persistence that separates a collection problem from a busy quarter.
24% of rev
FY2025
Key fundamentals
Net Margin-29.0%
Free Cash Flow-$19.3M
Latest Revenue$134.5M
Return on Equity-14.1%
Revenue CAGR (3yr)+40.0%
Revenue Growth YoY-3.9%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Rxsight, Inc.'s actual 10-K/10-Q/8-K filings?
Data from SEC EDGAR public filings · metrics as of Sep 6, 2026. Forensic signals flag probability, not certainty.
Rxsight, Inc. (RXST) Stock — Forensic Analysis, Red Flags & Rating | Stockonomy · Stockonomy
Stock-based comp load.
Stock-based compensation ran 24% of revenue in FY2025 — about $0.77 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 14.2% a year, and the rate is falling. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.